analyst
HR
NASDAQ · HROWM
Harrow Health, Inc. 11.875% Senior Notes due 2027
Healthcare · Medical - Pharmaceuticals
$26.03
Down-$0.02 (-0.08%)
Updated Oct 21, 2026, 3:00 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.34B
- P/E ratio
- -183.74
- Dividend yield
- 8.55%
- 52-week range
- — – —
- Volume
- 27.12K
- Avg. volume
- 10.55K
Price performance · HROWM
HROWM price history
1M range · 0 trading sessions · Daily adjusted prices
HROWM does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest HROWM news
The latest Smart Investors Daily articles mentioning HROWM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HROWM research
Overview
Company profile and research snapshot.
Company profile
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $34.93
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | BTIG | Buy | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Aug 11, 2026 | BTIG | Buy | — |
| Jul 21, 2026 | BTIG | Buy | — |
| May 13, 2026 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.